Biogenix Molecular

Miami, Florida 33165

1 studies enrolling now · 9 studies all time

What they study most

Biochemical Recurrence of Malignant Neoplasm of Prostate, Bronchial Neuroendocrine Tumor, Castration-Resistant, Clear Cell Renal Cell Carcinoma, Cryotherapy, Gastroenteropancreatic Neuroendocrine Tumor, Heart Failure With Preserved Ejection Fraction, Meningioma, Merkel Cell Carcinoma, Neuroendocrine Tumor Metastatic, Neuroendocrine Tumors Unresectable, Paraganglioma

Studies at this site

• Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors — Recruiting now
• A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer — Completed
• 89Zr-DFO-girentuximab Expanded Access Program (EAP) — NO_LONGER_AVAILABLE
• 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer — Running, not enrolling
• Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) — Stopped early
• 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE) — Completed
• 64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT) — Stopped early
• Global Prevalence of ATTR-CM in Participants With HFpEF — Stopped early
• Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer — Completed